

CONFIDENTIAL – NOT FOR PUBLIC INSPECTION



May 15, 2017

BY HAND DELIVERY

Marlene H. Dortch
Secretary
Federal Communications Commission
445 12th Street, SW
Washington, DC 20554

Attn: Evan Morris
Media Bureau

Re: Request for Confidential Treatment concerning Request for Waiver of Service Rules

Dear Ms. Dortch:

Pursuant to Section 0.459 of the Commission's Rules, 47 C.F.R. § 0.459, LocusPoint WDVb Licensee, LLC (licensee of WDVb-CD, Edison, NJ), and LocusPoint WLPD Licensee, LLC (licensee of WLPD-CD, Plano, IL) (collectively, "LocusPoint"), respectfully request that the Federal Communications Commission ("Commission") withhold from public inspection and afford confidential treatment to the attached Request for Waiver of Service Rules, which is marked "confidential" (the "Waiver Request"). LocusPoint asks that the Commission keep confidential certain portions of the Waiver Request, which is being submitted pursuant to section 6403(b)(4)(B) of the Middle Class Tax Relief and Job Creation Act of 2012 (the "Spectrum Act") and section 73.3700(f) of the Commission's rules, which allow for "flexible use of the spectrum assigned to the licensee to provide services other than broadcast television services." In addition to the unredacted version of the Waiver Request attached hereto, LocusPoint is filing a redacted, public version of the Waiver Request through the required LMS interface.

The Waiver Request contains confidential and commercially sensitive information and should be kept confidential and withheld from public inspection under the Commission's rules and the Freedom of Information Act ("FOIA").¹ Under Subsection 0.457(d) of the

¹ See 5 U.S.C. §§ 552(b)(3), (4); 47 C.F.R. §§ 0.457(c), (d).

CONFIDENTIAL – NOT FOR PUBLIC INSPECTION

Commission’s rules and FOIA Exemption 4, “trade secrets and commercial or financial information obtained from a person and privileged or confidential” are not required to be made available for public inspection.² Applying Exemption 4, courts have stated that commercial or financial information is confidential if its disclosure will either (1) impair the government’s ability to obtain necessary information in the future; or (2) cause substantial harm to the competitive position of the person from whom the information was obtained.³ As shown below, the information contained in the Waiver Request meets these criteria.

In the event that Commission determines that this Request for Confidential Treatment should be rejected, LocusPoint asks that the Commission provide LocusPoint with prior notice of at least three (3) business days so that it may request, if it so desires, that the Commission return the Waiver Request to it without consideration, as permitted under section 0.459(e) of the Commission’s rules. LocusPoint therefore requests that the Waiver Request receive confidential treatment throughout its pendency, as well as thereafter if it is returned without consideration.

In accordance with Section 0.459(b) of the Commission’s Rules, this request is supported by the following showing:

- 1) *Identification of the specific information for which confidential treatment is sought.* Confidential treatment is sought for the portions of the Waiver Request redacted in the publicly-filed version, which discuss LocusPoint’s plans for developing and delivering innovative and valuable non-broadcast services over certain broadcast TV station spectrum to which LocusPoint stations have been reassigned in the post-Incentive Auction repacking.
- 2) *Identification of the Commission proceeding in which the information was submitted or a description of the circumstances giving rise to the submission.* The Waiver Request is filed pursuant to section 6403(b)(4)(B) of the Spectrum Act and section 73.3700(f) of the Commission’s rules. The Commission established May 15, 2017 as the deadline for submitting such requests
- 3) *Explanation of the degree to which the information is commercial or financial, or contains a trade secret or is privileged.* The Confidential Waiver Request contains proprietary commercial information protected by Section 0.457(d). The courts have given the term “commercial,” as used in Section 552(b)(4), its ordinary meaning.⁴ The Commission has broadly defined commercial information, stating that “[c]ommercial’ is broader than information regarding basic commercial operations, such as sales and

² *Id.*

³ See *National Parks and Conservation Ass’n v. Morton*, 498 F.2d 765, 770 (D.C. Cir. 1974); see also *Critical Mass Energy Project v. NRC*, 975 F.2d 871, 879-80 (D.C. Cir. 1992).

⁴ See *Board of Trade v. Commodity Futures Trading Comm’n*, 627 F.2d 392, 403 & n.78 (D.C. Cir. 1980).

CONFIDENTIAL – NOT FOR PUBLIC INSPECTION

profits....”⁵ The proprietary information contained in the Waiver Request relates to innovative new wireless services that LocusPoint hopes to be able to offer in the competitive wireless marketplace and therefore falls squarely within this definition.

- 4) *Explanation of the degree to which the information concerns a service that is subject to competition.* The Waiver Request directly relates to the highly competitive businesses of wireless data services. Should the Waiver Request be granted, LocusPoint would enter the marketplace for wireless data services in New York and Chicago, two of the most populous and competitive local markets in the nation.
- 5) *Explanation of how disclosure of the information could result in substantial competitive harm.* Disclosure of the proprietary commercial information included in the Waiver Request would result in substantial competitive harm to LocusPoint by revealing to competitors sensitive commercial information – such as its innovative concepts for developing wireless data services that can be transmitted in the broadcast band – which competitors and other market participants could use to LocusPoint’s disadvantage.
- 6) *Identification of any measures taken by the submitting party to prevent unauthorized disclosure.* LocusPoint does not release the proprietary commercial information contained in the Waiver Request to the public in the normal course of business. LocusPoint maintains internal processes to ensure that such information is protected from public disclosure.
- 7) *Identification of whether the information is available to the public and the extent of any previous disclosure of the information to third parties.* LocusPoint does not release the proprietary commercial information contained in the Waiver Request to the public in the normal course of business and does not provide the proprietary commercial information contained in the Waiver Request to third parties except pursuant to arrangements that maintain confidentiality.
- 8) *Justification of the period during which the submitting party asserts that material should not be available for public disclosure.* LocusPoint respectfully requests that the Commission withhold the Confidential Waiver Request from public inspection indefinitely. LocusPoint would not, in the normal course of business, provide the proprietary commercial information contained therein to the public at any time.
- 9) *Any other information that the party seeking confidential treatment believes may be useful in assessing whether its request for confidentiality should be granted.* Public release of the proprietary commercial information contained in the Waiver Request would provide competitors of LocusPoint with inappropriate access to some of the

⁵ *Southern Company Request for Waiver of Section 90.629 of the Commission’s Rules*, Memorandum Opinion and Order, 14 FCC Rcd 1851, 1860 (1998) (citing *Public Citizen Health Research Group v. FDA*, 704 F.2d 1280, 1290 (D.C. Cir. 1983)).

CONFIDENTIAL – NOT FOR PUBLIC INSPECTION

company's most sensitive and innovative strategies and efforts to advance new technical developments.

For the foregoing reasons, we respectfully request that the Commission treat the Waiver Request as confidential and withhold it from public inspection.

Please stamp the enclosed additional copy of this filing and return it to the waiting messenger. Should you have any questions concerning this matter, please contact the undersigned.

Respectfully submitted,

By: /s/ William D. deKay
William D. deKay, Executive Chairman
Ravi Potharlanka, President and CEO
6200 Stoneridge Mall Road, Suite 300
Pleasanton, CA 94588
(925) 399-6352

Attachment

Of Counsel:
Bryan N. Tramont
Jonathan V. Cohen
WILKINSON BARKER KNAUER, LLP
1800 M Street, NW, Suite 800N
Washington, D.C. 20036
(202) 783-4141

May 15, 2017